Aclaris Therapeutics, Inc.
NASDAQAclaris Therapeutics has turned sharply lower, shedding 35% over the past week and 45% over the past month to close at $3.40, a brutal reversal for a stock that had been up nearly 79% year-to-date as recently as late September. The week's central tension is between a Street that remains uniformly bullish and a market that is voting hard the other way. The positioning picture is…
ACRS short interest surges 21.8% in one week to 9.7% of float, driven by skepticism over clinical pipeline progress.
Snapshot as of 17 Oct 2026
Aclaris Therapeutics has turned sharply lower, shedding 35% over the past week and 45% over the past month to close at $3.40, a brutal reversal for a stock that had been up nearly 79% year-to-date as recently as late…
Aclaris Therapeutics reports Q1 results this morning with options traders running their most defensive positioning of the past year — even as the analyst community has rarely been more constructive on the stock. The…
Aclaris Therapeutics reports Q1 results tomorrow morning with a setup that cuts several ways at once: a fresh analyst initiation, a put/call ratio at its highest level in a year, and short sellers holding a meaningful…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACRS — free to start on ORTEX.
Sign up for free →Open ACRS on ORTEX